Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys' AbD Serotec Unit to Provide Research Antibodies for Proteomika

NEW YORK (GenomeWeb News) — MorphoSys said today that Proteomika, a proteomics biomarker-discovery subsidiary of Progenika Biopharma, has ordered “multiple” research antibodies from its AbD Serotec business unit.
The agreement places Proteomika “among the largest customers for custom monoclonals services provided by AbD Serotec,” MorphoSys said, but did not disclose financial details.
Under the terms of the agreement, AbD Serotech will provide Proteomika with HuCal-based research antibodies against “a broad range of target molecules.”
Proteomika is involved in cancer-related in-house discovery projects at the bioGUNERResearch Institute, and has established research collaborations for non-invasive diagnostics, pharmacoproteomics markers, and novel therapeutic targets.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.